Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Operating Margin (2020 - 2025)

Vivos Therapeutics' Operating Margin history spans 6 years, with the latest figure at 166.89% for Q4 2025.

  • Quarterly results put Operating Margin at 166.89% for Q4 2025, down 9101.0% from a year ago — trailing twelve months through Dec 2025 was 114.08% (down 3975.0% YoY), and the annual figure for FY2025 was 114.05%, down 3973.0%.
  • Operating Margin for Q4 2025 was 166.89% at Vivos Therapeutics, down from 69.79% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 198.22% in Q4 2021 to a low of 182.19% in Q1 2022.
  • The 5-year median for Operating Margin is 124.15% (2021), against an average of 101.93%.
  • The sharpest move saw Operating Margin soared 38717bps in 2021, then plummeted -35172bps in 2022.
  • Year by year, Operating Margin stood at 198.22% in 2021, then crashed by -177bps to 153.49% in 2022, then rose by 17bps to 127.25% in 2023, then soared by 40bps to 75.88% in 2024, then plummeted by -120bps to 166.89% in 2025.
  • According to Business Quant data, Operating Margin over the past three periods came in at 166.89%, 69.79%, and 127.36% for Q4 2025, Q3 2025, and Q2 2025 respectively.